Exact Sciences Licenses Freenome’s Blood-Based Cancer Tests
Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket...
Category : Healthcare Quality, Patient Safety & Policy
Collette Health, Dr. Clipper Partner on Virtual Care
Strategic consulting partnership leverages Dr. Clipper’s expertise in virtual nursing implementation and optimization to enhance Collette Health’s platform capabilities and market leadership Collette Health, the...
FDA Accepts Priority Review for Bristol Myers Squibb’s Breyanzi
Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results...
Concept Medical Enrolls First Patient in MAGICAL-SV Trial
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions...
Raytone Biotech Doses First Patient in RTP-008 Eye Trial
Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of...
Integrated Dermatology Adds NP Katie O’Brien in MA
Integrated Dermatology, the country’s largest independent dermatology provider, proudly announces that Katie O’Brien, MSN, ANP-BC, has joined its partner practice, The Dermatology Center of Worcester. A...
Sarepta Issues Statement on ELEVIDYS Patient Death
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the...
BeOne’s TEVIMBRA Gets CHMP Nod for NSCLC Treatment
Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival and major pathological response If...
Malaysia Launches MYMT 2026, Its 1st Medical Tourism Year
The Malaysia Healthcare Travel Council (MHTC) launched Malaysia Year of Medical Tourism (MYMT) 2026 today at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk...
IDEAYA & Hengrui to Present IDE849 at IASLC 2025 Lung Cancer Conf
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and...
Humana Speeds Up Prior Authorization Removal for Faster Care
New effort will expedite approvals, promote access to care, reduce administrative burdens, and enhance the patient experience Humana Inc., a leading health and well-being company,...
MVP Health & Renalytix Partner to Expand Kidney Disease Testing
New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities. Renalytix Plc, a precision medicine...
Cybin Gets MHRA OK to Start EMBRACE Study of CYB003 for MDD
– EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe...
AdventHealth, Anthem Sign Multi-Year Deal to Expand GA Access
AdventHealth and Anthem Blue Cross Blue Shield of Georgia (Anthem) are pleased to announce a new multi-year contractual agreement that ensures continued access to high-quality,...
Alzheon to Share ALZ-801 Data at Alzheimer’s Conference July 30′
Valiltramiprosate Evaluated in APOLLOE4 Trial, First Interventional Phase 3 Alzheimer’s Trial Focused on High-Risk APOE4/4 Homozygotes Anti-Amyloid Oligomer Action Underpins Valiltramiprosate’s Potential Benefit in Alzheimer’s...